NEW
Actemra IV

Actemra IV Indications/Uses

tocilizumab

Manufacturer:

Roche

Distributor:

Zuellig Pharma
Full Prescribing Info
Indications/Uses
Rheumatoid Arthritis (RA): Tocilizumab is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients. Tocilizumab can be used alone or in combination with methotrexate (MTX) and/or other disease-modifying anti-rheumatic drugs (DMARDs). Tocilizumab has been shown to reduce the rate of progression of joint damage as measured by X-Ray and to improve physical function when given in combination with methotrexate (MTX).
Coronavirus disease 2019 (COVID-19): Tocilizumab is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
Polyarticular Juvenile Idiopathic Arthritis (pJIA): Tocilizumab in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX.
Tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.
Systemic Juvenile Idiopathic Arthritis (sJIA): Tocilizumab is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. Tocilizumab can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in